Abiomed Receives FDA Approval for Impella CP with SmartAssist and Optical Sensor

Medical Device Investing

Abiomed (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its Impella CP heart pump with SmartAssist, utilizing an optical sensor. At the forefront of innovation, these advances in technology and software are designed to improve productivity, ease …

Abiomed (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its Impella CPheart pump with SmartAssist, utilizing an optical sensor. At the forefront of innovation, these advances in technology and software are designed to improve productivity, ease of use, and patient management to ensure optimal patient care.

As quoted in the press release:

“The ability to view fundamental hemodynamic data such as LVP, EDP and CPO directly on the Impella console provides critical information for clinical decision-making,” said William O’Neill, Medical Director, Center for Structural Heart Disease, Henry Ford Hospital. “Additionally, access to data and real-time pump position improves efficiency for nurses and physicians in the ICU and CCU.”

Click here to read the full press release.

approval disease fda food and drug administration innovation patient pma Medical Device Investing